
Edmond de Rothschild Private Equity
Description
Edmond de Rothschild Private Equity, a prominent division of the global Edmond de Rothschild Group, is a leading player in the European private equity landscape, headquartered in Paris, France. The firm specializes in managing and advising on investments in unlisted assets, focusing on long-term value creation across various strategies. Their approach emphasizes active partnership with management teams to foster growth and transformation in portfolio companies.
The private equity arm boasts significant scale, managing over €12 billion (approximately $13 billion USD) in assets under management as of early 2024. This capital is deployed across a diverse range of strategies, including growth capital, buyouts, infrastructure debt, and life sciences. Their investment philosophy is rooted in deep sector expertise and a commitment to responsible investment, integrating ESG factors into their decision-making processes to ensure sustainable value creation.
A key part of their equity strategy is exemplified by their Winch Capital funds, which target growth equity investments in French and European small and medium-sized enterprises (SMEs). For these growth-oriented equity deals, Edmond de Rothschild Private Equity typically provides initial equity tickets ranging from €15 million to €50 million (approximately $16.2 million to $54 million USD). Since its inception, the private equity business line has invested in over 100 companies, demonstrating a robust track record of supporting businesses through various stages of development and expansion.
Investor Profile
Edmond de Rothschild Private Equity has backed more than 20 startups, with 2 new investments in the last 12 months alone. The firm has led 5 rounds, about 25% of its total and boasts 8 exits across its portfolio.
Investment Focus Highlights
- Concentrates on Series B, Series C, Series A rounds (top funding stages).
- Majority of deals are located in Switzerland, France, Germany.
- Strong thematic focus on Biotechnology, Pharmaceutical, Health Care.
- Typical check size: $16.2M – $54M.
Stage Focus
- Series B (20%)
- Series C (15%)
- Series A (15%)
- Private Equity (15%)
- Series Unknown (10%)
- Debt Financing (10%)
- Post Ipo Debt (10%)
- Post Ipo Equity (5%)
Country Focus
- Switzerland (25%)
- France (25%)
- Germany (15%)
- United States (15%)
- United Kingdom (10%)
- The Netherlands (5%)
- Italy (5%)
Industry Focus
- Biotechnology
- Pharmaceutical
- Health Care
- Biopharma
- Medical
- Therapeutics
- Manufacturing
- Internet
- Energy
- Energy Management
Frequently Asked Questions
Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.